Zhi Tong Cai Jing·2025-09-12 06:11Core Viewpoint - Nuo Cheng Jian Hua (09969) experienced a significant stock price increase of 12.96%, reaching HKD 19, with a trading volume of HKD 406 million following the approval of its drug Ibrutinib (Yinokai) for treating relapsed/refractory marginal zone lymphoma (R/R MZL) in Singapore [1] Company Developments - On September 8, Nuo Cheng Jian Hua announced that Ibrutinib received approval from the Health Sciences Authority (HSA) of Singapore for treating adult patients with R/R MZL, marking the second indication approved in Singapore [1] - Ibrutinib has already been approved in China for treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), relapsed/refractory mantle cell lymphoma (R/R MCL), and R/R MZL, all of which are included in the national medical insurance [1] Financial Performance - According to Western Securities (002673), Nuo Cheng Jian Hua achieved revenue of CNY 731 million in the first half of 2025, representing a year-on-year growth of 74.3% [1] - Sales of the core product Ibrutinib reached CNY 637 million, reflecting a year-on-year increase of 52.8% [1] - The approval of Ibrutinib for the new indication of first-line CLL/SLL has been recommended as a level 1 treatment in the 2025 CSCO lymphoma guidelines, enhancing its market potential in hematological malignancies [1] Product Pipeline - In May 2025, the company’s second innovative drug, Tanxizhuo Monoclonal Antibody, was approved for use in combination with Lenalidomide for treating relapsed/refractory DLBCL, further enriching the company's commercial product portfolio [1]